1575815-63-2

Upstream product

• 1575815-60-9 methyl 4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzoate 
• 1575815-59-6 2-chloro-4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidine 
• 1260088-95-6 2,4-dichloro-6,7-dihydro-5H-pyrano[2,3-d]pyrimidine 
• 946828-44-0 2,4-bis(methylsulfonyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidine 
• 946828-37-1 2,4-bis(methylthio)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidine 
• 542-28-9 3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1575815-61-0 4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzoic acid 
• 81863-45-8 3-(hydroxymethyl)-6-methylaniline 

Downstream Products

• 1575815-64-3 N-(5-(chloromethyl)-2-methylphenyl)-4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzamide 
• 1575815-65-4 N-(2-methyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzamide 
• 1575815-66-5 N-(2-methyl-5-(morpholinomethyl)phenyl)-4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzamide 
• 1575815-67-6 N-(2-methyl-5-(pyrrolidin-1-ylmethyl)phenyl)-4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzamide 
• 1575815-68-7 N-(5-((diethylamino)methyl)-2-methylphenyl)-4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzamide 
• 1575815-69-8 N-(5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-methylphenyl)-4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzamide 
• 1575815-70-1 N-(5-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)-2-methylphenyl)-4-((4-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl)amino)benzamide 

Relevant academic research and scientific papers

A diaryl tetrapyran and pyrimidine derivatives and their medical use

The invention relates to a dihydropyran pyrimidine derivatives with the structure of formula (I), and (or) pharmaceutically acceptable salts, and pharmaceutical application thereof as Hedgehog signal transduction inhibitors.

Design, synthesis, and biological study of 6,7-dihydro-5H-pyrano[2,3-d] pyrimidine derivatives as novel hedgehog signaling pathway inhibitors

A novel series of hedgehog signaling pathway inhibitors were designed by replacing the pyrimidine nucleus of our earlier reported compounds with 6,7-dihydro-5H-pyrano[2,3-d]pyrimidine scaffold. Among this new class of hedgehog signaling pathway inhibitors, compounds 14 and 18 exhibited promising potency in vitro compared to GDC-0449. Compound 18 was advanced to profile its pharmacokinetic characteristics, and showed moderate pharmacokinetic properties in vivo, indicating that the 6,7-dihydro-5H-pyrano[2,3-d]pyrimidine skeleton is a promising scaffold for further exploration as hedgehog signaling pathway inhibitors. Springer Science+Business Media 2014.